TANDEM DIABETES CARE INC (TNDM)
US8753722037 - Common Stock
We assign a fundamental rating of 3 out of 10 to TNDM. TNDM was compared to 192 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of TNDM have multiple concerns. TNDM is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year TNDM has reported negative net income.
TNDM had a negative operating cash flow in the past year.
In the past 5 years TNDM reported 4 times negative net income.
TNDM had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
TNDM has a Return On Assets (-23.38%) which is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -71.01%, TNDM is in line with its industry, outperforming 41.03% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -23.38% | ||
| ROE | -71.01% | ||
| ROIC | N/A |
ROA(3y)-10.21%
ROA(5y)-8.61%
ROE(3y)-29.63%
ROE(5y)-22.2%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TNDM has a Gross Margin of 49.18%. This is comparable to the rest of the industry: TNDM outperforms 42.56% of its industry peers.
TNDM's Gross Margin has been stable in the last couple of years.
TNDM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 49.18% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.99%
GM growth 5Y0.14%
2. Health
2.1 Basic Checks
TNDM does not have a ROIC to compare to the WACC, probably because it is not profitable.
TNDM has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, TNDM has more shares outstanding
TNDM has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 1.47, we must say that TNDM is in the distress zone and has some risk of bankruptcy.
TNDM's Altman-Z score of 1.47 is in line compared to the rest of the industry. TNDM outperforms 55.90% of its industry peers.
A Debt/Equity ratio of 0.91 indicates that TNDM is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.91, TNDM is not doing good in the industry: 76.41% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.91 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.47 |
ROIC/WACCN/A
WACC9.67%
2.3 Liquidity
A Current Ratio of 3.83 indicates that TNDM has no problem at all paying its short term obligations.
TNDM has a Current ratio (3.83) which is in line with its industry peers.
TNDM has a Quick Ratio of 3.02. This indicates that TNDM is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.02, TNDM is in line with its industry, outperforming 60.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.83 | ||
| Quick Ratio | 3.02 |
3. Growth
3.1 Past
TNDM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -215.15%.
Looking at the last year, TNDM shows a decrease in Revenue. The Revenue has decreased by -6.68% in the last year.
TNDM shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 32.38% yearly.
EPS 1Y (TTM)-215.15%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-8%
Revenue 1Y (TTM)-6.68%
Revenue growth 3Y14.45%
Revenue growth 5Y32.38%
Revenue growth Q2Q-10.75%
3.2 Future
The Earnings Per Share is expected to grow by 17.28% on average over the next years. This is quite good.
The Revenue is expected to grow by 11.13% on average over the next years. This is quite good.
EPS Next Y47.9%
EPS Next 2Y28.17%
EPS Next 3Y21.3%
EPS Next 5Y17.28%
Revenue Next Year10.79%
Revenue Next 2Y11.15%
Revenue Next 3Y10.78%
Revenue Next 5Y11.13%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TNDM. In the last year negative earnings were reported.
Also next year TNDM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as TNDM's earnings are expected to grow with 21.30% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.17%
EPS Next 3Y21.3%
5. Dividend
5.1 Amount
TNDM does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TANDEM DIABETES CARE INC
NASDAQ:TNDM (4/26/2024, 7:20:02 PM)
After market: 35.24 0 (0%)35.24
-0.32 (-0.9%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.31B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -23.38% | ||
| ROE | -71.01% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 49.18% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.78
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.91 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.83 | ||
| Quick Ratio | 3.02 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-215.15%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y47.9%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-6.68%
Revenue growth 3Y14.45%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y